Results 31 to 40 of about 3,549 (185)

Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil

World Journal of Surgical Oncology, 2019
Background The docetaxel, 5-fluorouracil, and cisplatin (DCF) regimen is an effective form of chemotherapy for advanced esophageal cancer. However, the incidence of adverse events such as febrile neutropenia and hematological toxicity is high.
Yu Ohkura, Masaki Ueno, Harushi Udagawa
doaj   +1 more source

Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure [PDF]

, 2020
Febrile neutropenia (FN) is a serious complication of chemotherapy, which can cause significant morbidity and mortality, result in dose delays and reductions and, ultimately, reduce cancer survival.
Vulto, Arnold, Gascon, Pere, Gascon, P, Vulto, Arnold; id_orcid, Gascon, P. (Pere), Aapro, Matti, Cornes, P, Aapro, M, Aapro, M. (Matti), Cornes, Paul, Cornes, P. (Paul), Vulto, Arnold G., Vulto, A.G. (Arnold)   +12 more
core   +1 more source

Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis)

BMC Cancer, 2021
Background A classification tree was used to analyze background factors for granulocyte colony-stimulating factor (G-CSF) preparation selection for febrile neutropenia (FN) prophylaxis in Japanese patients with non-Hodgkin B-cell lymphoma receiving the ...
Masahiro Yokoyama, Yoshiharu Kusano, Norihito Inoue, Noriko Nishimura, Yuko Mishima, Tomoyuki Nukada, Kiyohiko Hatake, Yasuhito Terui   +7 more
doaj   +1 more source

A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin’s lymphoma receiving chemotherapy

Haematologica, 2008
Background Growth factors are frequently used to aid peripheral blood progenitor cell mobilization from bone marrow. This phase 2 study examined the efficacy and safety of pegfilgrastim for mobilizing peripheral blood progenitors cells for autologous ...
Nigel Russell, Rolf Mesters, Joerg Schubert, Marc Boogaerts, Hans E. Johnsen, Consuelo del Canizo, Nigel Baker, Philippa Barker, Tomas Skacel, Norbert Schmitz   +9 more
doaj   +1 more source

Two decades of pegfilgrastim: what have we learned? Where do we go from here?

, 2023
Chemotherapy-induced febrile neutropenia (FN) is a medical emergency that may occur in patients with malignancies receiving myelosuppressive chemotherapy.
Darcie Sandschafer (11377093), Jeffrey Crawford (8978418), Sandra Lewis (14851606), Cisio De Oliveira Brandao (14851603)   +3 more
core   +1 more source

A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy‐induced neutropenia in patients with early‐stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study

Cancer Medicine, 2020
Eflapegrastim (Rolontis®) is a novel, long‐acting hematopoietic growth factor consisting of a recombinant human granulocyte‐colony stimulating factor (rhG‐CSF) analog conjugated to a human IgG4 Fc fragment via a short polyethylene glycol linker.
Patrick Wayne Cobb, Yong Wha Moon, Klára Mezei, István Láng, Gajanan Bhat, Shanta Chawla, Steven J. Hasal, Lee S. Schwartzberg   +7 more
doaj   +1 more source

A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant. [PDF]

PLoS ONE, 2013
PurposeTo assess the non-inferiority of pegfilgrastim versus filgrastim in speeding the recovery of polymorphonuclear cells (PMN) in pediatric patients who underwent autologous peripheral blood stem cell transplant (PBSCT).MethodsThe sample size of this ...
Simone Cesaro, Francesca Nesi, Gloria Tridello, Massimo Abate, Irene Sara Panizzolo, Rita Balter, Elisabetta Calore   +6 more
doaj   +1 more source

Bone Pain Associated with Once-Per-Cycle Pegfilgrastim Is Similar to Daily Filgrastim in Patients with Breast Cancer

, 2003
Bone pain is a common side effect of treatment with filgrastim. Pegfilgrastim is a pegylated long-acting analogue of filgrastim that is administered once per chemotherapy cycle.
Glaspy, John, Ann Holmes, Frankie, Hackett, James, Kubista, Ernst, on behalf of the Pegfilgrastim Study Group, Green, Michael D, Neumann, Theresa   +6 more
core   +1 more source

Demonstration of Physicochemical and Functional Similarity of Biosimilar Pegfilgrastim-cbqv to Pegfilgrastim

Drugs in R&D
Background Pegfilgrastim-cbqv/CHS-1701 (UDENYCA®) (hereafter referred to as pegfilgrastim-cbqv) was approved in 2018 by the US Food and Drug Administration as a biosimilar for pegfilgrastim (Neulasta®) (hereafter referred to as pegfilgrastim).
Henriette Kuehne, Janice M. Davis, LeeAnne Merewether, Matthew McQueen, Elizabeth Valentine, Glen Young, Benjamin T. Andrews, Dimitri Diaz, Karen J. Miller   +8 more
doaj   +1 more source

An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer

Breast, 2023
Purpose: Pegfilgrastim is a widely used long-acting granulocyte colony-stimulating factor (G-CSF) that prevents febrile neutropenia (FN) in patients with breast cancer receiving chemotherapy.
Anbok Lee, Taewoo Kang, Su Hwan Kang, Woo-Chan Park, Woosung Lim, Myung-Chul Chang, Hyun Yul Kim, Jeong-yoon Song, Jihyoun Lee, Kyung Do Byun, Hyun-Ah Kim, Gil Soo Son, Ju-Yeon Kim, Se Jeong Oh, Min Sung Chung, Young Jin Choi, Hyuk-Jai Shin, Jong Min Baek, Youngbum Yoo, Eunhae Um, Jin Hyuk Choi, Beom Seok Kwak, Min Ho Park, Suok Hyun Lee, Cheol Seung Kim, Ilkyun Lee, Je-Ryong Kim, Han Shin Lee, Cheol Wan Lim   +28 more
doaj   +1 more source